Wendi Qian

9.0k total citations · 1 hit paper
82 papers, 4.3k citations indexed

About

Wendi Qian is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wendi Qian has authored 82 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 24 papers in Pathology and Forensic Medicine and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wendi Qian's work include Lymphoma Diagnosis and Treatment (22 papers), Viral-associated cancers and disorders (14 papers) and CNS Lymphoma Diagnosis and Treatment (12 papers). Wendi Qian is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Viral-associated cancers and disorders (14 papers) and CNS Lymphoma Diagnosis and Treatment (12 papers). Wendi Qian collaborates with scholars based in United Kingdom, Australia and United States. Wendi Qian's co-authors include Mahesh Parmar, Andrew Jack, David C. Linch, Ann Marie Swart, Paul Smith, Henry C Kitchener, David Cunningham, John Radford, Kirit M. Ardeshna and Peter Johnson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Wendi Qian

79 papers receiving 4.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

2013 357 citations David Cunningham, Andrew Jack et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wendi Qian United Kingdom	26	2.3k	2.0k	799	763	659	82	4.3k
Paul Hoskins Canada	37	2.2k 1.0×	2.4k 1.2×	1.3k 1.6×	582 0.8×	808 1.2×	131	5.5k
Gerasimos Aravantinos Greece	36	2.3k 1.0×	428 0.2×	833 1.0×	1.2k 1.6×	187 0.3×	205	4.5k
Saul E. Rivkin United States	40	3.6k 1.6×	815 0.4×	352 0.4×	2.0k 2.6×	350 0.5×	127	5.8k
R. S. Bush Canada	35	934 0.4×	920 0.5×	625 0.8×	898 1.2×	324 0.5×	75	3.4k
Khédoudja Nafa United States	41	3.0k 1.4×	1.8k 0.9×	461 0.6×	3.0k 4.0×	215 0.3×	93	7.6k
Richard Fisher Australia	37	2.5k 1.1×	495 0.3×	224 0.3×	1.8k 2.3×	140 0.2×	112	6.2k
D. Spooner United Kingdom	30	3.8k 1.7×	785 0.4×	149 0.2×	3.4k 4.5×	332 0.5×	111	6.4k
Andrés Poveda Spain	39	2.3k 1.0×	829 0.4×	2.5k 3.1×	2.2k 2.9×	181 0.3×	157	5.8k
Antonio Casado Spain	33	2.5k 1.1×	506 0.3×	2.4k 3.1×	1.5k 1.9×	147 0.2×	178	5.7k
Annamaria Ferrero Italy	32	1.2k 0.5×	187 0.1×	1.4k 1.7×	373 0.5×	281 0.4×	168	3.4k

Countries citing papers authored by Wendi Qian

Since Specialization

Citations

This map shows the geographic impact of Wendi Qian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendi Qian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendi Qian more than expected).

Fields of papers citing papers by Wendi Qian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendi Qian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendi Qian. The network helps show where Wendi Qian may publish in the future.

Co-authorship network of co-authors of Wendi Qian

This figure shows the co-authorship network connecting the top 25 collaborators of Wendi Qian. A scholar is included among the top collaborators of Wendi Qian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendi Qian. Wendi Qian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marzolini, Maria A. V., Wendi Qian, Laura Clifton‐Hadley, et al.. (2024). Quality of life in advanced‐stage, asymptomatic, non‐bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful‐waiting. British Journal of Haematology. 206(3). 876–886. 2 indexed citations

Dosanjh, Davinder, Thomas F. Hiemstra, Alex Richter, et al.. (2023). PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V). Trials. 24(1). 185–185. 3 indexed citations

Watts, Colin, Alimu Dayimu, Tomasz Matys, et al.. (2023). Refining the Intraoperative Identification of Suspected High-Grade Glioma Using a Surgical Fluorescence Biomarker: GALA BIDD Study Report. Journal of Personalized Medicine. 13(3). 514–514. 3 indexed citations

Raine, Tim, Wendi Qian, Gordon W. Moran, et al.. (2022). Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut. 71(4). 661–664.

Ursprung, Stephan, Andrew N. Priest, Fulvio Zaccagna, et al.. (2021). Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. PLoS ONE. 16(10). e0258988–e0258988. 4 indexed citations

Qian, Wendi, et al.. (2020). Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut. 70(4). 677–686. 47 indexed citations

Dayimu, Alimu, Wendi Qian, Bingbing Fan, et al.. (2019). Trajectories of Haemoglobin and incident stroke risk: a longitudinal cohort study. BMC Public Health. 19(1). 1395–1395. 9 indexed citations

Matys, Tomasz, Sarojini David, Doris M. Rassl, et al.. (2018). Routine preoperative brain CT in resectable non-small cell lung cancer – Ten years experience from a tertiary UK thoracic center. Lung Cancer. 122. 195–199. 7 indexed citations

Pacey, Simon, Nimish Shah, Ola Bratt, et al.. (2017). CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).. Journal of Clinical Oncology. 35(6_suppl). 97–97.

10.

Earl, Helena, Anne-Laure Vallier, Wendi Qian, et al.. (2017). PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.. Journal of Clinical Oncology. 35(15_suppl). TPS591–TPS591. 11 indexed citations

11.

Rossi, Antônio, Massimo Di Maïo, Paolo Chiodini, et al.. (2012). Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. Journal of Clinical Oncology. 30(14). 1692–1698. 381 indexed citations

12.

Lowry, Lisa, Paul Smith, Wendi Qian, et al.. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiotherapy and Oncology. 100(1). 86–92. 247 indexed citations

13.

Rustin, Gordon, Clare Griffin, David Guthrie, et al.. (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet. 376(9747). 1155–1163. 355 indexed citations

14.

Linch, David C., Lynny Yung, Paul Smith, et al.. (2010). Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. British Journal of Haematology. 149(2). 237–243. 10 indexed citations

15.

Hoskin, Peter, Lisa Lowry, Alan Horwich, et al.. (2009). Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology. 27(32). 5390–5396. 124 indexed citations

16.

Linch, David C., Wendi Qian, John F. Seymour, et al.. (2009). Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leukemia & lymphoma. 50(2). 211–215. 20 indexed citations

17.

Haynes, Andrew, Andrew McMillan, Andrew Jack, et al.. (2006). A Prospective, Randomised Trial of Chlorambucil, Mitoxantrone and Dexamethasone (CMD) Versus Fludarabine, Mitoxantrone and Dexamethasone (FMD) for Advanced Follicular Lymphoma (Real Grades I-III, Stages III/IV).. Blood. 108(11). 534–534. 1 indexed citations

18.

Bojke, Laura, Mark Sculpher, Richard Stephens, et al.. (2006). Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer. PharmacoEconomics. 24(5). 443–452. 6 indexed citations

19.

Ledermann, JA, N. Colombo, Andreas du Bois, et al.. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (vol 361, pg 2099, 2003). UCL Discovery (University College London). 2 indexed citations

20.

Girling, D.J., et al.. (2002). Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. Seminars in Oncology. 29(1). 97–101. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact